1105 related articles for article (PubMed ID: 32068819)
1. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
2. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
3. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
4. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
5. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.
Baumeister SE; Holtfreter B; Reckelkamm SL; Kocher T; Alayash Z; Ehmke B; Baurecht H; Nolde M
J Clin Periodontol; 2023 Jan; 50(1):114-120. PubMed ID: 36054135
[TBL] [Abstract][Full Text] [Related]
6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
7. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
[TBL] [Abstract][Full Text] [Related]
8. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
[TBL] [Abstract][Full Text] [Related]
9. Association between Genetically Proxied Inhibition of HMG-CoA Reductase and Age at Onset of Huntington's Disease.
Zhu Y; Li M; Wang H; Yang F; Wang J; Huang X
Brain Sci; 2022 Nov; 12(11):. PubMed ID: 36421875
[TBL] [Abstract][Full Text] [Related]
10. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
11. Association of Common and Rare Genetic Variation in the 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Gene and Cataract Risk.
Ghouse J; Ahlberg G; Skov AG; Bundgaard H; Olesen MS
J Am Heart Assoc; 2022 Jun; 11(12):e025361. PubMed ID: 35703387
[TBL] [Abstract][Full Text] [Related]
12. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
14. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q
JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045
[TBL] [Abstract][Full Text] [Related]
15. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
[TBL] [Abstract][Full Text] [Related]
16. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
[TBL] [Abstract][Full Text] [Related]
17. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
18. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.
Yarmolinsky J; Díez-Obrero V; Richardson TG; Pigeyre M; Sjaarda J; Paré G; Walker VM; Vincent EE; Tan VY; Obón-Santacana M; Albanes D; Hampe J; Gsur A; Hampel H; Pai RK; Jenkins M; Gallinger S; Casey G; Zheng W; Amos CI; ; ; ; Smith GD; Martin RM; Moreno V
PLoS Med; 2022 Feb; 19(2):e1003897. PubMed ID: 35113855
[TBL] [Abstract][Full Text] [Related]
19. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.
Ma L; Du Y; Ma C; Liu M
Front Endocrinol (Lausanne); 2023; 14():1272167. PubMed ID: 38047111
[TBL] [Abstract][Full Text] [Related]
20. Low LDL cholesterol,
Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
[No Abstract] [Full Text] [Related]
[Next] [New Search]